|Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market|
Home / News
Takeda Completes its Russian Pharmaceutical Manufacturing FacilityTakeda Pharmaceutical International GmbH today announced the completion of construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia. The Company has invested approximately 75 million in the 24,000m2 production plant, which is expected to be fully operational by 2014.
Takeda was one of the first major international companies to have invested in high quality pharmaceutical manufacturing in Russia, demonstrating its long-term commitment to the market. Based on sales Takeda is the 7th largest pharmaceutical company in Russia. According to IMS Health, Russian pharmaceutical sales totaled $14.7 billion in 2011, making it the 11th largest pharmaceutical market in the world.
Market sales in Russia/CIS are expected to grow at a compound annual rate of 11% between 2012 and 2016. Takeda plans to outgrow the market with an annual growth rate of 15% over the same period.
The Yaroslavl facility will enable Takeda to meet demand in Russia, initially Cardiomagnyl, Actovegin and Calcium tablets. It will lead to creation of initially around 200 positions for highly qualified managers and technical staff.
The plant, which is approximately 280 kilometers from Moscow, was constructed on time and on budget to local and international GMP standards and adheres to the latest safety and environmental standards. It will have the initial capacity to manufacture 90 million sterile ampoules and more than two billion tablets per year.
Liquid sterile production includes solution preparation, washing of ampoules, sterilization, filling, inspection, and packaging. Solid production will encompass all stages, from weighing, mixing and granulation through compression, coating, and packaging.
"The completion of this ambitious project further demonstrates Takeda's transition into a truly global business, and strategic investment into key emerging markets such as Russia is a major part of this strategy." said Yasuchika Hasegawa, President & Chief Executive Officer of Takeda Pharmaceutical Company Limited. "Russia is our largest emerging market in terms of revenues, and is expected to contribute significantly to our growth over the next few years. The Yaroslavl facility will enable us to provide locally produced pharmaceutical products to patients and clinicians, as well as bringing significant benefits to the Yaroslavl and Russian economy." "Takeda is one of the flagship companies in Yaroslavl's pharmaceutical cluster and is the first major international pharmaceutical company to invest in a new world class manufacturing facility in the region," added Sergey Yastrebov, the Governor of Yaroslavl Region. "This project is an excellent example of the benefits that international investment can bring to the Russian economy. Takeda is working closely with Russian companies to build the plant, and will create hundreds of high quality jobs for Russian people in the future."